TRVI News and Press, Trevi Therapeutics Inc. From 09/04/19

Quick Take BELLUS Health ( BLU ) has filed to raise gross proceeds of $60 million from a U.S. IPO, according to an F-10 registration statement . The firm is developing therapeutics for chronic cough and other hypersensitization disorders. BLU is in the middle of Phase 2 trials for its l...

Trevi Therapeutics (NASDAQ: TRVI ): Q2 net loss of $7.3M More news on: Trevi Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

NEW HAVEN, Conn., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced financial results fo...

The following slide deck was published by Trevi Therapeutics, Inc. in conjunction with this Read more ...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you ca...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...

NEW HAVEN, Conn., June 18, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that Company managem...

Trevi Therapeutics (NASDAQ: TRVI ): Q1 net loss of $4.8M More news on: Trevi Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Raised $70 Million in Gross Proceeds from Initial Public Offering and Concurrent Private Placement Initiated Phase 2 Clinical Trial for Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF)   NEW HAVEN, Conn., June 13, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, I...

Gainers:  Provention Bio (NASDAQ: PRVB ) +296% . Vuzix Corporation (NASDAQ: VUZI ) +54% . Xynomic Pharmaceuticals Holdings (NASDAQ: XYN ) +46% . Tableau Software (NYSE: DATA ) +35% . Hi-Crush (NYSE: HCR ) +31% . Beyond Meat (NASDAQ: BYND ) +24% . Workhorse Group (NASDAQ: WKHS ) ...